1 hr ago
Dr Lal PathLabs to Acquire 70% Stake in SN Genelab
Dr Lal PathLabs plans to buy most of another diagnostics company called SN Genelab.
SN Genelab is based in Gujarat and provides genomics testing services.
Dr Lal PathLabs will pay about ₹168 crore for a 70% share.
The agreement may also include up to ₹31.5 crore based on the company’s performance.
If the deal is completed, SN Genelab will become a subsidiary of Dr Lal PathLabs.
The acquisition is intended to expand Dr Lal PathLabs’ genomics and advanced testing services.
The transaction is expected to be completed by November 30, 2026.
SN Genelab earned ₹57.96 crore in turnover during FY26.
The filing said the deal is not a related-party transaction and does not need government or regulatory approvals.
Dr Lal PathLabs’ board approved acquiring a 70% stake in Gujarat-based SN Genelab for approximately ₹168 crore.
The deal includes a performance-linked earn-out component capped at ₹31.5 crore.
SN Genelab will become a subsidiary of Dr Lal PathLabs after the transaction is completed.
Dr Lal PathLabs said the acquisition will strengthen its genomics expertise and advanced diagnostic services portfolio.
SN Genelab reported turnover of ₹57.96 crore in FY26, up from ₹53.36 crore in FY25 and ₹43.27 crore in FY24.
- Who
- Dr Lal PathLabs and Gujarat-based diagnostic genomics company SN Genelab.
- What
- Dr Lal PathLabs’ board approved the proposed acquisition of a 70% stake in SN Genelab for approximately ₹168 crore, plus a potential earn-out.
- Where
- SN Genelab is based in Gujarat, and the announcement was issued from New Delhi.
- When
- The announcement was made on September 24; completion is expected by November 30, 2026.
- Why
- To strengthen Dr Lal PathLabs’ genomics expertise and expand its advanced diagnostic services portfolio.
Key facts
- Acquiring company
- Dr Lal PathLabs Ltd
- Target company
- SN Genelab
- Stake
- 70%
- Base transaction value
- Approximately ₹168 crore
- Maximum earn-out
- ₹31.5 crore
- Expected completion
- November 30, 2026
- SN Genelab FY26 turnover
- ₹57.96 crore
- Regulatory approvals
- Not required, according to the filing
Sources
Related news
Indo Borax Secures ₹225 Crore Funding for Kronox Acquisition
Metropolis Healthcare targets technology-led growth amid local consolidation
Sudarshan Pharma Targets US Market With MedTherapy Stake Deal
Aster DM Subsidiary Acquires 14.21% Stake in STS Holdings
Preventive Health Checks Gain Ground Across India’s Diagnostic Industry
Stocks in Focus as Companies Report Deals, Results, Changes
BSE, LIC, HDFC Bank Among Stocks in Focus Today
Three Smallcap Stocks Show Breakout Potential
